This question has likely been covered before, and apologies if so but,
Has anyone crunched the numbers and come to a potential Market Cap/Share price if:
- Daybue sales continue as projected.
- NNZ-2591 is successful in the 4 indications being trialed.
- The target market for those 4 indications truly is 5x larger than Rett syndrome.
- NEU reaches an agreement similar to what we did with ACADIA (including upfront and milestone payments etc).
- No TO is accepted, NEU partners with either ACADIA or someone similar.
If we essentially do with NNZ-2591 what we've done with Trofinetide, what kind of number(s) do we end up with??
I'm sure ive seen a few valuation models from various learned posters here, but can anyone refresh our memory? Have models changed in light of today's success?
Many thanks in advance.
What a brilliant day for the NEU team, we investors, but most importantly, the families living with these conditions.
This question has likely been covered before, and apologies if...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.08 |
Change
0.380(2.99%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.08 | $12.89 | $6.969M | 536.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 1142 | $13.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.08 | 1518 | 5 |
View Market Depth
| Last trade - 15.56pm 17/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |